The U.S. Patent and Trademark Office (USPTO) has awarded two new patents to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering methods of the CRISPR-Cas9 gene-editing technology.
Dr. Jake Micallef, Chief Scientific Officer of Volition, commented, "Our worldwide portfolio of granted patents that protects various aspects of Volition's Nu.QTM technology is growing.